Get started
Author

Frank Holtrup

Observed name: F. Holtrup
OpenAlex ID: A5069108659
Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
2016 · Inga Medina Diaz, Annette Nocon, et al. · PLoS ONE · 201
PDF
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
2019 · Begona Jimenez Rodriguez, Gema Diaz Córdoba, et al. · Journal of Clinical Medicine · 60
Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology
2023 · Inga Medina Diaz, Annette Nocon, et al. · Diagnostics · 52
PDF
Microarray analysis of nemorosone‐induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR)
2010 · Frank Holtrup, Andrea Bauer, et al. · British Journal of Pharmacology · 35
PDF
Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
2020 · Jonathan M. Loree, Anthony Dowers, et al. · Clinical Cancer Research · 30
Demand Response Potentials for the Chemical Industry
2017 · Franziska Klaucke, Tim Karsten, et al. · Chemie Ingenieur Technik · 30
Comparison of the cytotoxic effects of enantiopure PPAPs, including nemorosone and clusianone
2012 · Nigel S. Simpkins, Frank Holtrup, et al. · Bioorganic & Medicinal Chemistry Letters · 26
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS
2016 · Johannes Fredebohm, Daniel H. Mehnert, et al. · Advances in experimental medicine and biology · 21
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment
2022 · Ari J. Rosenberg, Evgeny Izumchenko, et al. · BMC Cancer · 17
PDF
In Vivo Activity and Pharmacokinetics of Nemorosone on Pancreatic Cancer Xenografts
2013 · Robert J. Wolf, Ralf A. Hilger, et al. · PLoS ONE · 16
PDF
Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies
2021 · Jessica Garcia, Arnaud Gauthier, et al. · Molecular Diagnosis & Therapy · 10
PDF
Replication and Virus-Induced Transcriptome of HAdV-5 in Normal Host Cells versus Cancer Cells - Differences of Relevance for Adenoviral Oncolysis
2011 · Dominik E. Dorer, Frank Holtrup, et al. · PLoS ONE · 9
PDF
Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.
2021 · Hillary Sloane, Evgeny Izumchenko, et al. · Journal of Clinical Oncology · 6
Blood-based testing of mutations in patients with head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
2019 · F. Fostira, P. Oikonomopoulou, et al. · Annals of Oncology · 5
Abstract LB053: Clinical evaluation of NGS-based liquid biopsy genotyping in non-small cell lung cancer (NSCLC) patients
2021 · Hillary Sloane, Priya Sathyanarayan, et al. · Cancer Research · 2
Abstract P6-10-05: TBCRC 040: Pathologic response evaluation and detection in circulating tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer
2020 · Natasha Hunter, Heather Parsons, et al. · Cancer Research · 2
Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.
2018 · Begona Jimenez Rodriguez, Gema Diaz Córdoba, et al. · Journal of Clinical Oncology · 2
2012 Concordance of RAS mutation status in metastatic CRC patients bycomparison of results from circulating tumor DNA and tissue-based RAS testing
2015 · F. Jones, D. Edelstein, et al. · European Journal of Cancer · 2
164P Rapid liquid biopsy genotyping in NSCLC patients
2021 · P. Sathyanarayan, H. Sloane, et al. · Journal of Thoracic Oncology · 1
Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors
2026 · Maria Clark, Ramadevi Prathapam, et al. · Journal of Molecular Diagnostics
Reproducibility and clinical concordance of a tumor-informed MRD assay in patients with resected colorectal cancer from the DYNAMIC trials.
2026 · Jeanne Tie, Hillary S. Sloane, et al. · Journal of Clinical Oncology
PDF
Supplemental Figure 1 from Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
2023 · Jonathan M. Loree, Anthony Dowers, et al.
Supplemental Tables and Figure Caption from Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
2023 · Jonathan M. Loree, Anthony Dowers, et al.
Data from Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
2023 · Jonathan M. Loree, Anthony Dowers, et al.
Data from Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
2023 · Jonathan M. Loree, Anthony Dowers, et al.
Works count: 29
Citation count: 527
H-index: 10
I10-index: 11
Year
Topic
Type